{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.583","upperLimit":"4.03","value":"1.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.5","upperLimit":"6.07","value":"1.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Tmax of capmatinib was estimated by non-compartmental analysis. Tmax is the time to reach maximum plasma concentration. Actual recorded sampling times were considered for the calculations. Plasma concentrations of capmatinib were measured using validated LCMS/MS methods with a LLOQ of approximately 1.0 ng/mL.\n\nOnly a subset of participants from Cohorts 1a, 1b, 2, 3, 4, 5a and 5b, who had an extensive PK collection schedule, were included in this analysis","dispersionType":"Full Range","groups":[{"description":"Participants from Cohorts 1a, 1b, 2, 3, 4, 5a and 5b who received capmatinib in fasted state","id":"OG000","title":"Cohorts 1-5: Capmatinib Administration in Fasted State"}],"paramType":"MEDIAN","populationDescription":"Participants from Cohorts 1a, 1b, 2, 3, 4, 5a and 5b who received at least one dose of capmatinib with extensive PK sampling collection and an evaluable PK parameter (Tmax for capmatinib) at the specified time points. Participants received capmatinib under the same administration conditions (fasted state) and were pooled together for analysis","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Day 15 at pre-dose, 0.5, 1, 2, 4, 6 and 8 hours post-dose. Each Cycle is 21 days","title":"Time to Reach Maximum Concentration (Tmax) of Capmatinib","type":"SECONDARY","unitOfMeasure":"hour"}